RA

Rashi Agrawal

Active Director Director DIN 00007115
DIN 00007115 First appointment Mar 2024 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2024
Shareholding value •••• Premium profile

About Rashi Agrawal

Data last updated:

Rashi Agrawal is a Director at Zeneris Pharma Private Limited (since 2024). The company operates in Pharma. Zeneris Pharma Private Limited reported revenue of ₹3.50 Cr (FY 2025).

DIN 00007115
Primary Designation Director
Industry Pharma
First Appointment 30 Mar 2024
Oldest Company Age 10 yrs
Largest company Zeneris Pharma Private Limited · ₹3.50 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Zeneris Pharma Private Limited U33100DL2016PTC302689
Director30 Mar 20242016₹3.50 Cr (FY 2025)Active

Board colleagues of Rashi Agrawal

NameDINCompanyDesignation
Aditya Agrawal05250489Zeneris Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Zeneris Pharma Private Limited
Premium access

Shareholding and investment profile for Rashi Agrawal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rashi Agrawal

Rashi Agrawal currently holds 1 directorship: Zeneris Pharma Private Limited (Director, since 30 Mar 2024, revenue ₹3.50 Cr (FY 2025)).

Rashi Agrawal was first appointed on 30 Mar 2024 as Director at Zeneris Pharma Private Limited.

The current boards of Rashi Agrawal's companies include Aditya Agrawal (Zeneris Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available